Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C

Journal of Hepatology

Volumn 40, Issue 5, 2004, Pages 845-852

  Mihm, Ulrike ^a   Herrmann, Eva ^a,b   Sarrazin, Ulrike ^a   Von Wagner, Michael ^a   Kronenberger, Bernd ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

ALT, alanine aminotransferase; AST, aspartate aminotransferase; bDNA, branched DNA; ETR, end of treatment responder(s) with relapse; HCV, hepatitis C virus; Hepatitis C virus RNA; Interferon resistance; Interleukin 8; Non structural 5A; Virologic response

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 8; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERLEUKIN-8; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 1942535074     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.01.007     Document Type: Conference Paper

References (53)

1. El Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 36:2002;S74-S83.
2. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology. 36:2002;S21-S29.
3. Seeff L.B. Natural history of chronic hepatitis C. Hepatology. 36:2002;S35-S46.
4. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
5. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
6. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 37:2003;600-609.
7. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., Peters M., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 315:1986;1575-1578.
8. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 339:1998;1485-1492.
9. Witherell G.W., Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol. 63:2001;8-16.
10. Duverlie G., Khorsi H., Castelain S., Jaillon O., Izopet J., Lunel F., et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol. 79:1998;1373-1381.
11. Nousbaum J., Polyak S.J., Ray S.C., Sullivan D.G., Larson A.M., Carithers R.L. Jr, Gretch D.R. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol. 74:2000;9028-9038.
12. Sarrazin C., Herrmann E., Bruch K., Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 76:2002;11079-11090.
13. Sarrazin C., Berg T., Lee J.H., Teuber G., Dietrich C.F., Roth W.K., Zeuzem S. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 30:1999;1004-1013.
14. Sarrazin C., Kornetzky I., Ruster B., Lee J.H., Kronenberger B., Bruch K., et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology. 31:2000;1360-1370.
15. Francois C., Duverlie G., Rebouillat D., Khorsi H., Castelain S., Blum H.E., et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 74:2000;5587-5596.
16. Paterson M., Laxton C.D., Thomas H.C., Ackrill A.M., Foster G.R. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology. 117:1999;1187-1197.
17. Podevin P., Sabile A., Gajardo R., Delhem N., Abadie A., Lozach P.Y., et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology. 33:2001;1503-1511.
18. Polyak S.J., Paschal D.M., McArdle S., Gale M.J. Jr, Moradpour D., Gretch D.R. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology. 29:1999;1262-1271.
19. Gale M. Jr, Blakely C.M., Kwieciszewski B., Tan S.L., Dossett M., Tang N.M., et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 18:1998;5208-5218.
20. Girard S., Shalhoub P., Lescure P., Sabile A., Misek D.E., Hanash S., et al. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology. 295:2002;272-283.
21. Polyak S.J., Khabar K.S., Paschal D.M., Ezelle H.J., Duverlie G., Barber G.N., et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol. 75:2001;6095-6106.
22. Neuman M.G., Benhamou J.P., Martinot M., Boyer N., Shear N.H., Malkiewicz I. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem. 32:1999;537-545.
23. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol. 75:2001;6209-6211.
24. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 352:1998;1426-1432.
25. Poynard T., McHutchison J., Goodman Z., Ling M.H., Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 31:2000;211-218.
26. Sarrazin C., Teuber G., Kokka R., Rabenau H., Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology. 32:2000;818-823.
27. Konnick E.Q., Erali M., Ashwood E.R., Hillyard D.R. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol. 40:2002;768-773.
28. Ross R.S., Viazov S., Sarr S., Hoffmann S., Kramer A., Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods. 101:2002;159-168.
29. Simmonds P., Holmes E.C., Cha T.A., Chan S.W., McOmish F., Irvine B., et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 74:1993;2391-2399.
30. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
31. Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol. 55:1994;97-179.
32. Oppenheim J.J., Zachariae C.O., Mukaida N., Matsushima K. Properties of the novel proinflammatory supergene 'intercrine' cytokine family. Annu Rev Immunol. 9:1991;617-648.
33. Taub D.D., Oppenheim J.J. Chemokines, inflammation and the immune system. Ther Immunol. 1:1994;229-246.
34. Khabar K.S., Al Zoghaibi F., Murayama T., Matsushima K., Mukaida N., Siddiqui Y., et al. Interleukin-8 selectively enhances cytopathic effect (CPE) induced by positive-strand RNA viruses in the human WISH cell line. Biochem Biophys Res Commun. 235:1997;774-778.
35. Khabar K.S., Al Zoghaibi F., Al Ahdal M.N., Murayama T., Dhalla M., Mukaida N. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med. 186:1997;1077-1085.
36. Kato N., Yoshida H., Kioko Ono-Nita S., Kato J., Goto T., Otsuka M. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. 32:2000;405-412.
37. Balasubramanian A., Ganju R.K., Groopman J.E. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem. 278:2003;35755-35766.
38. Oliveira I.C., Sciavolino P.J., Lee T.H., Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA. 89:1992;9049-9053.
39. Schnyder-Candrian S., Strieter R.M., Kunkel S.L., Walz A. Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. J Leukoc Biol. 57:1995;929-935.
40. Bosco M.C., Gusella G.L., Espinoza-Delgado I., Longo D.L., Varesio L. Interferon-gamma upregulates interleukin-8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood. 83:1994;537-542.
41. Yasumoto K., Okamoto S., Mukaida N., Murakami S., Mai M., Matsushima K. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J Biol Chem. 267:1992;22506-22511.
42. Kaplanski G., Farnarier C., Payan M.J., Bongrand P., Durand J.M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci. 42:1997;2277-2284.
43. Ben Baruch A., Michiel D.F., Oppenheim J.J. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem. 270:1995;11703- 11706.
44. Mawet E., Shiratori Y., Hikiba Y., Takada H., Yoshida H., Okano K., et al. Cytokine-induced neutrophil chemoattractant release from hepatocytes is modulated by Kupffer cells. Hepatology. 23:1996;353-358.
45. Napoli J., Bishop G.A., McCaughan G.W. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology. 107:1994;789-798.
46. Okamura K., Noshima S., Esato K. Cytokine release during hypoxia reoxygenation by Kupffer cells in rats with obstructive jaundice. Surg Today. 29:1999;730-734.
47. Sheron N., Bird G., Koskinas J., Portmann B., Ceska M., Lindley I., Williams R. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology. 18:1993;41-46.
48. Thornton A.J., Strieter R.M., Lindley I., Baggiolini M., Kunkel S.L. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J Immunol. 144:1990;2609-2613.
49. Thornton A.J., Ham J., Kunkel S.L. Kupffer cell-derived cytokines induce the synthesis of a leukocyte chemotactic peptide, interleukin-8, in human hepatoma and primary hepatocyte cultures. Hepatology. 14:1991;1112-1122.
50. Shimoda K., Begum N.A., Shibuta K., Mori M., Bonkovsky H.L., Banner B.F., Barnard G.F. Interleukin-8 and hIRH (SDF1-alpha/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology. 28:1998;108-115.
51. Mukaida N., Shiroo M., Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 143:1989;1366-1371.
52. Chayama K., Tsubota A., Kobayashi M., Hashimoto M., Miyano Y., Koike H., et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology. 23:1996;953-957.
53. McHutchison J.G., Ponnudurai R., Bylund D.L., Anguiano A., Pockros P.J., Mondala T., Wilkes L.B. Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial. J Clin Gastroenterol. 32:2001;133-137.